Full Press Release Details
Tiziana Life Sciences Ltd. Regains Compliance
with Nasdaq Listing Minimum Bid Price Rule
2023 -- Tiziana Life Sciences Ltd.. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing
breakthrough immunomodulation therapies via novel routes of drug delivery, today announces that it has received a notification from the
Nasdaq Stock Market LLC ("Nasdaq") Listing Qualifications Department informing the Company that it has regained compliance
with the Nasdaq listing minimum bid price requirement for continued listing on the Nasdaq Capital Market exchange.
Tiziana was previously notified
by Nasdaq on June 14, 2022 that it was not in compliance with the minimum bid-price listing rule (under Rule 5550(a)(2)) because
its common stock failed to meet the closing bid price of $1.00 or more for 30 consecutive business days. To regain compliance,
the Company was required to maintain a minimum closing bid price of $1.00 or more for at least ten consecutive trading days
which was met on April 20, 2023.
Tiziana Life Sciences is
a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable
alternative routes of immunotherapy. Tiziana's innovative nasal approach has the potential to provide an improvement in efficacy
as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana's lead candidate, intranasal foralumab,
which is the only fully human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical response in patients in studies to
date. Tiziana's technology for alternative routes of immunotherapy has been patented with several applications pending and is expected
to allow for broad pipeline applications.
For further inquiries:
Tiziana Life Sciences Ltd